2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Jump to: View All • a b [c] d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 052

Case Series: Treatment of Refractory Lung Disease in Systemic Juvenile Idiopathic Arthritis with Cyclophosphamide and Rituximab Combination Therapy
Abstract Number: 043

Challenges of Cognitive Screening and Formal Neuropsychological Evaluation in Youth with Childhood-Onset Systemic Lupus Erythematosus: A Survey of CARRA Providers
Abstract Number: 090

Characterizing CNS MRI Abnormalities in Pediatric ANCA-Associated Vasculitis
Abstract Number: 031

Clinical Characteristics and Diagnostic Predictors of Inflammatory Bowel Disease in Patients with Chronic Nonbacterial Osteomyelitis – A Single Center Retrospective Analysis
Abstract Number: 106

Clinical Characteristics and Safety Outcomes in Refractory Kawasaki Disease Treated with Second-Dose Infliximab
Abstract Number: 048

Clinical characteristics of childhood-onset primary Sjögren’s syndrome in South Korea: two centers’ experiences
Abstract Number: 099

Clinical Features of Juvenile Antisynthetase Syndrome: A Single-Center Case Series

Jump to: View All • a b [c] d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].